Optigenex Inc. Announces Rollout of Activar(R) AC-11(R) Oral Supplements and Activar(R) AC-11(R) Next Generation Skin Care Products in Turkey Through Its Middle Eastern Distribution Partner Ekson Farma, Istanbul

NEW YORK, NY--(Marketwire - July 28, 2009) -

Optigenex Inc. (PINKSHEETS: OPGX) announced today its partner Ekson Farma is prepared to launch its family of AC-11® oral supplements and skin care products under the brand name Activar® for distribution throughout the major pharmacies in Turkey. Under an exclusive license signed in early 2008, Ekson has invested significant capital, resources and time in determining market acceptance of Optigenex’s patented technology and has also devoted considerable efforts towards clinical and scientific research to broaden the market applications for its unique anti-aging products. The agreement and subsequent commercialization by Ekson sets the stage for the introduction of AC-11® to educated and health-conscious Turkish consumers and represents another important strategic initiative in the company’s plans to establish AC-11® as a recognized international brand.

All-natural, and standardized at a minimum of 8 per cent Carboxy Alkyl Esters (“CAEs™"), AC-11® is the only patented aqueous extract of the Uncaria species that can make the following therapeutic claims (“DNA repair, Immune enhancement and Inhibition of pro-inflammatory agents”) which are validated by a broad spectrum of scientific and clinical studies.

AC-11® already has gained a major foothold in Japan and has been introduced in other select territories of Asia as a branded ingredient used by over 100 manufacturers and distributors in a variety of anti-aging cosmetic, cosmeceutical and dietary supplement products. With their regional alliance together, Optigenex and Middle Eastern based Ekson Farma anticipate similar market penetration, growth and expansion for AC-11®

Daniel Zwiren, president and CEO of Optigenex Inc., said, “We are delighted to have a company with the scientific pedigree and reputation of Ekson Farma as part of our growing list of marketing and distribution partners. Moreover, we believe the unique scientific properties of AC-11® along with Ekson’s research will allow us to grow our business rapidly in this key geographic region.”

Doctor Yaman Er, president of Ekson Farma, added, “We are very pleased with the reception AC-11® has received and attribute this attention to the key differentiators of AC-11® supported by clinical and scientific studies. Those studies validate the efficacy of this all-natural ingredient, which is harvested in the Amazon Rainforest and manufactured by Centroflora Group Botucatu, Brazil. Consumer demand in our market is driven by new and result-oriented technologies. We believe our alliance with Optigenex provides us with the opportunity to introduce Turkey and the Middle East to the next major brand in oral and topical applications.”

About Ekson Farma:

Ekson Farma: Founded in 1994, Ekson Farma is an applied sciences and marketing company focused on providing wellness solutions and related technologies to physicians, pharmacies and the general medical community. Ekson’s strategy is to select superior and innovative products validated by clinical and scientific studies, establish consumer and physician acceptance through test marketing and ultimately distribute those products with the goal of improving the quality of life for health conscious consumers and patients. Ekson through its collaboration with research partner OKSANTE LABORATORIES is noted for its development of diagnostic tools utilizing DNA sequencing and molecular diagnostics with an emphasis on early detection of disease and DNA mutations.

About Optigenex Inc.:

Optigenex Inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11® (Formerly known as C-MED-100®) a patented compound, as it core product. AC-11® is a bioactive, water-soluble form of the medicinal herb Uncaria tomentosa. For more information about Optigenex please email or call the company at: dzwiren@optigenex.com 201 355 2098.

* The statements made in this press release have not been evaluated by the Food and Drug Administration. The products mentioned in this release are not intended to diagnose, treat, cure or prevent any disease.